慢性疾病和动脉粥样硬化异质性的概念化作为精确药物的途径：内骨型，内型和残留心血管风险

评论：EDNRA =内皮素受体类型a;PHACTR1 =磷酸酶和肌动蛋白调节器1;Gucy1a3 =胍基环酶1可溶性亚基α1;CNNM2 = Cyclin和CBS结构域二价金属阳离子输送介质2;CYP17A1 =细胞色素P450系列17亚家族A会员1;sort1 = sortilin 1;FGF5 =成纤维细胞生长因子5;HNF1A =肝细胞核因子1 Homeobox A;SH2B3 = SH2B适配器蛋白3;pecam1 =血小板内皮细胞粘附分子1; CXCL12=C-X-C motif ligand 12; ANGPTL3=angiopoietin-like protein 3; PPP1R3B=protein phosphatase 1 regulatory subunit 3B; CTRB1/2=chymotrypsinogen B1; SMAD3=mothers against decapentaplegic homolog 3; NOS3=nitric oxide synthase 3; LDLR=low-density lipoprotein receptor; PCSK9=proprotein convertase subtilisin/kexin type 9; APOB=apolipoprotein B; sdLDL=small dense low-density lipoproteins; ADAMTS=a disintegrin and metalloproteinase with thrombospondin motifs; THBS2=thrombospondin-2; CFDP1=craniofacial development protein 1; NOX4=NADPH oxidase 4; MCP-1=monocyte chemoattractant protein 1; M-CSF=macrophage colony-stimulating factor; VCAM-1=vascular cell adhesion molecule 1; IL-6R=interleukin-6 receptor; HNF1A=hepatocyte nuclear factor 1 homeobox A; TNF=tumor necrosis factor; IL=interleukin; hsCRP=high-sensitivity C-reactive protein; sCD40L=soluble CD40 ligand.